Craft

Sanofi

Stock Price

€100

2024-10-29

Market Capitalization

€126.4 B

2024-08-26

Revenue

€45.4 B

FY, 2025

Sanofi Summary

Company Summary

Overview
Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. It is organized around a Biopharma operating segment that specializes in immunology and inflammation, rare diseases, neurology, oncology, other medicines, and vaccines. It develops treatment for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, rheumatoid arthritis, etc.
Type
Public
Status
Active
Founded
1994
HQ
Paris, FR | view all locations
Website
https://www.sanofi.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Paul Hudson

    Paul Hudson, Chief Executive Officer & Director

  • Olivier Charmeil

    Olivier Charmeil, Executive Vice President, General Medicines

  • Natalie Bickford

    Natalie Bickford, Executive Vice President, Chief People Officer

  • Julie van Ongevalle

    Julie van Ongevalle, Executive Vice President, Consumer Healthcare

    Operating MetricsView all

    Phase II Trials Products (Oncology)

    12
    100.0%

    FY, 2021

    Phase III/Filed Trials Products (Oncology)

    2
    66.7%

    FY, 2021

    Phase I Trials Products (Rare Blood Disorders)

    4

    FY, 2020

    LocationsView all

    105 locations detected

    • Paris, IDF HQ

      France

      54 Rue la Boétie

    • Bridgewater, NJ

      United States

      55 Corporate Dr

    • Cambridge, MA

      United States

      38 Sidney St

    • Cambridge, MA

      United States

      50 Binney St

    • Wilmington, DE

      United States

      1209 Orange St

    • Wilmington, DE

      United States

      3711 Kennett Pike Suite #200

    and 99 others

    Sanofi Financials

    Summary Financials

    Revenue (Q1, 2026)
    €10.5B
    Gross profit (Q1, 2026)
    €8.4B
    Net income (Q1, 2026)
    €1.6B
    Cash (Q1, 2026)
    €5.5B
    EBIT (Q1, 2026)
    €2.1B
    Enterprise value
    $140.8B

    Footer menu